Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MET-2 in Major Depression and Generalized Anxiety Disorder
NCT04052451Phase 1Completed
- Sponsor
- NuBiyota
- Start
- May 2019
- Primary completion
- May 2020
- Modality
- Live Biotherapeutic Products
- Countries
- 1
01
Overview
Phase 1, open-label trial of MET-2 in major depressive disorder (MDD) and generalized anxiety disorder (GAD) (2 arms), sponsored by NuBiyota. Primary endpoints: Montgomery-Asberg Depression Rating Scale at 10 weeks and Generalized Anxiety Disorder - 7 at 10 weeks. Started May 2019; status: completed.
02
Drugs
MET-2
03
Conditions
major depressive disorder (MDD)generalized anxiety disorder (GAD)
Beyond the preview
Go deeper on NCT04052451.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04052451.